- Home
- TBPH vs DDI Comparison
TBPH vs DDI Comparison
Compare TBPH & DDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBPH
- DDI
- Stock Information
- Founded
- TBPH 2013
- DDI 2008
- Country
- TBPH United States
- DDI South Korea
- Employees
- TBPH N/A
- DDI N/A
- Industry
- TBPH Biotechnology: Pharmaceutical Preparations
- DDI EDP Services
- Sector
- TBPH Health Care
- DDI Technology
- Exchange
- TBPH Nasdaq
- DDI Nasdaq
- Market Cap
- TBPH 485.8M
- DDI 519.3M
- IPO Year
- TBPH N/A
- DDI 2021
- Fundamental
- Price
- TBPH $9.15
- DDI $10.39
- Analyst Decision
- TBPH Buy
- DDI Strong Buy
- Analyst Count
- TBPH 4
- DDI 3
- Target Price
- TBPH $13.75
- DDI $22.67
- AVG Volume (30 Days)
- TBPH 166.7K
- DDI 36.3K
- Earning Date
- TBPH 02-24-2025
- DDI 02-11-2025
- Dividend Yield
- TBPH N/A
- DDI N/A
- EPS Growth
- TBPH N/A
- DDI N/A
- EPS
- TBPH N/A
- DDI 2.30
- Revenue
- TBPH $63,192,000.00
- DDI $342,458,000.00
- Revenue This Year
- TBPH $11.41
- DDI N/A
- Revenue Next Year
- TBPH $37.36
- DDI $1.30
- P/E Ratio
- TBPH N/A
- DDI $4.56
- Revenue Growth
- TBPH 15.93
- DDI 13.42
- 52 Week Low
- TBPH $7.44
- DDI $8.28
- 52 Week High
- TBPH $10.44
- DDI $18.21
- Technical
- Relative Strength Index (RSI)
- TBPH 49.84
- DDI 38.74
- Support Level
- TBPH $8.35
- DDI $10.20
- Resistance Level
- TBPH $8.86
- DDI $10.83
- Average True Range (ATR)
- TBPH 0.29
- DDI 0.52
- MACD
- TBPH -0.05
- DDI 0.11
- Stochastic Oscillator
- TBPH 58.39
- DDI 22.14
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
About DDI DoubleDown Interactive Co. Ltd. American Depository Shares
DoubleDown Interactive Co Ltd is a developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multi-format interactive entertainment experiences for casual players. Its market opportunity includes casual gaming globally, which includes slots, puzzles, cards, match three, and other similar games. Within the social casino segment of casual gaming, which includes free-to-play online slots, poker, table games, and bingo. Other games developed by the company are DoubleDown Fort, DoubleDown Classic, and Ellen's Road to Riches. The company has a presence in the international market, and it derives a majority of its revenue from the United States of America.